SLGL Stock Overview
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Sol-Gel Technologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.86 |
| 52 Week High | US$4.20 |
| 52 Week Low | US$0.79 |
| Beta | 1.32 |
| 1 Month Change | -17.58% |
| 3 Month Change | -26.45% |
| 1 Year Change | -77.53% |
| 3 Year Change | -93.98% |
| 5 Year Change | -88.15% |
| Change since IPO | -93.69% |
Recent News & Updates
Recent updates
Will Sol-Gel Technologies (NASDAQ:SLGL) Spend Its Cash Wisely?
Feb 28
Here's Why We're Watching Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Situation
Nov 07Companies Like Sol-Gel Technologies (NASDAQ:SLGL) Are In A Position To Invest In Growth
Jul 21Sol-Gel Technologies GAAP EPS of $0.01 beats by $0.11, revenue of $3.5M misses by $1.11M
Aug 04These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat
May 17We Think That There Are Issues Underlying Sol-Gel Technologies' (NASDAQ:SLGL) Earnings
Apr 15Downgrade: Here's How Analysts See Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Performing In The Near Term
Apr 05We Think Sol-Gel Technologies (NASDAQ:SLGL) Can Afford To Drive Business Growth
Nov 23We Think Sol-Gel Technologies (NASDAQ:SLGL) Needs To Drive Business Growth Carefully
Aug 04Here's Why Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) CEO May Deserve A Raise
Jul 01Sol-Gel says no FDA notification regarding its marketing application for EPSOLAY
Apr 27Newsflash: Sol-Gel Technologies Ltd. (NASDAQ:SLGL) Analysts Have Been Trimming Their Revenue Forecasts
Mar 05We're Not Very Worried About Sol-Gel Technologies' (NASDAQ:SLGL) Cash Burn Rate
Feb 02What Type Of Returns Would Sol-Gel Technologies'(NASDAQ:SLGL) Shareholders Have Earned If They Purchased Their SharesYear Ago?
Dec 29
FDA accepts Sol-Gel application for Twyneo
Dec 07Sol-Gel: Slow And Steady Topical Technology
Nov 19These Analysts Think Sol-Gel Technologies Ltd.'s (NASDAQ:SLGL) Sales Are Under Threat
Nov 18Sol-Gel Technologies EPS beats by $0.09, beats on revenue
Nov 12Shareholder Returns
| SLGL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -2.9% | -3.3% | -3.1% |
| 1Y | -77.5% | 11.3% | 20.9% |
Return vs Industry: SLGL underperformed the US Pharmaceuticals industry which returned 11.5% over the past year.
Return vs Market: SLGL underperformed the US Market which returned 22.4% over the past year.
Price Volatility
| SLGL volatility | |
|---|---|
| SLGL Average Weekly Movement | 13.1% |
| Pharmaceuticals Industry Average Movement | 9.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLGL's share price has been volatile over the past 3 months.
Volatility Over Time: SLGL's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 36 | Alon Seri-Levy | www.sol-gel.com |
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; SGT-610, a rare disease for the treatment of Gorlin Syndrome which has completed Phase II clinical trials; and Erlotinib and Tapinarof to treat other rare skin indications. It is also involved in the development of generic topical dermatological drug products.
Sol-Gel Technologies Ltd. Fundamentals Summary
| SLGL fundamental statistics | |
|---|---|
| Market cap | US$23.40m |
| Earnings (TTM) | -US$27.24m |
| Revenue (TTM) | US$1.55m |
15.4x
P/S Ratio-0.9x
P/E RatioIs SLGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLGL income statement (TTM) | |
|---|---|
| Revenue | US$1.55m |
| Cost of Revenue | US$23.54m |
| Gross Profit | -US$21.99m |
| Other Expenses | US$5.25m |
| Earnings | -US$27.24m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.98 |
| Gross Margin | -1,414.86% |
| Net Profit Margin | -1,752.77% |
| Debt/Equity Ratio | 0% |
How did SLGL perform over the long term?
See historical performance and comparison